Mammary Gland-Specific Expression of Biologically Active Human Osteoprotegerin in Transgenic Mice
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Osteoprotegerin (OPG) is a secreted glycoprotein that regulates bone resorption by inhibiting differentiation and activation of osteoclast, thereby potentially useful for the treatment of many bone diseases associated with increased bone loss. In this study, we designed a novel cDNA expression cassette by modifying the potent and mammary glandspecific goat β-casein/hGH hybrid gene construct and examined human OPG (hOPG) cDNA expression in transgenic mice. Six transgenic mice all successfully expressed hOPG in their milk at the level of 0.06—2,000 μg/ml. An estimated molecular weight of the milk hOPG was 55 kDa in SDS-PAGE, which is the same as a naturally glycosylated monomer. This hOPG expression was highly specific to the mammary glands of transgenic mice. hOPG mRNA was not detected in any organs analyzed except mammary gland. Functional integrity of milk hOPG was evaluated by TRAP (tartrate-resistant acid phosphatase) activity assay in bone marrow cell cultures. OPG ligand (OPG-L) treatment increased TRAP activity by two fold but it was completely abolished by co-treatment with transgenic milk containing hOPG. Taken together, our novel cDNA expression cassette could direct an efficient expression of biologically active hOPG, a potential candidate pharmaceutical for bone diseases, only in the mammary gland of transgenic mice.
Abstract
Osteoprotegerin (OPG) is a secreted glycoprotein that regulates bone resorption by inhibiting differentiation and activation of osteoclast, thereby potentially useful for the treatment of many bone diseases associated with increased bone loss. In this study, we designed a novel cDNA expression cassette by modifying the potent and mammary glandspecific goat β-casein/hGH hybrid gene construct and examined human OPG (hOPG) cDNA expression in transgenic mice. Six transgenic mice all successfully expressed hOPG in their milk at the level of 0.06—2,000 μg/ml. An estimated molecular weight of the milk hOPG was 55 kDa in SDS-PAGE, which is the same as a naturally glycosylated monomer. This hOPG expression was highly specific to the mammary glands of transgenic mice. hOPG mRNA was not detected in any organs analyzed except mammary gland. Functional integrity of milk hOPG was evaluated by TRAP (tartrate-resistant acid phosphatase) activity assay in bone marrow cell cultures. OPG ligand (OPG-L) treatment increased TRAP activity by two fold but it was completely abolished by co-treatment with transgenic milk containing hOPG. Taken together, our novel cDNA expression cassette could direct an efficient expression of biologically active hOPG, a potential candidate pharmaceutical for bone diseases, only in the mammary gland of transgenic mice.
참고문헌 (29)
- Akers RM, "Radioimmunoassay for measurement of bovine alpha-lactalbumin in serum, milk and tissue culture media", J Dairy Res, 53, pp.419~429 (1986)
- Anandarajah AP, "Role of RANKL in bone diseases", Trends Endocrinol Metab, 20, pp.88~94 (2009)
- Dyck MK, "Making recombinant proteins in animals-different systems, different applications", Trends Biotechnol, 21, pp.394~399 (2003)
- Echelard Y, "Production of recombinant therapeutic proteins in the milk of transgenic animals", BioPharm Int, 2, pp.1~6 (2006)
- Filgueira L, "Osteoclast differentiation and function, In Bone Cancer", pp.59~66 (2010), Academic Press
- Grabowski H, "Rabbit whey acidic protein concentration in milk, serum, mammary gland extract, and culture medium", J Dairy Sci, 74, pp.4143~4150 (1991)
- Heymann D, "Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences", J Bone Oncol, 1, pp.2~11 (2012)
- Kostenuik PJ, "Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength", Curr Opin Pharmacol, 5, pp.618~625 (2005)
- Kues WA, "Advances in farm animal transgenesis", Prev Vet Med, 102, pp.146~156 (2011)
- Lacey DL, "Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo", Am J Pathol, 157, pp.435~448 (2000)
- Lacey DL, "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", Cell, 93, pp.165~176 (1998)
- Lamoureux F, "Regulation of osteoprotegerin proor anti-tumoral activity by bone tumor microenvironment", Biochim Biophys Acta, 1805, pp.17~24 (2010)
- 이철상, "Goat β-casein Promoter Directs hGH Expression at a High Level and in a Mammary-Specific Manner in Transgenic Mice", Genes & Genomics, 28(2), pp.131~137 (2006), 한국유전학회
- Liu JZ, "Expression of human osteoprotegerin gene in E. coli and bioactivity analysis of expression product", Zhonghua Wai Ke Za Zhi, 41, pp.641~645 (2003)
- Maga EA, "Mammary gland expression of transgenes and the potential for altering the properties of milk", Biotechnology (NY), 13, pp.1452~1456 (1995)
- Min H, "Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis", J Exp Med, 192, pp.463~474 (2000)
- 오건봉, "Characterization of Double Transgenic Mice Harboring Both Goat β-casein", hGH and Goat β-casein, 발생과 생식, pp.2009, 13(3)[DOI]
- 오건봉, "Co-expression of IRES-mediated hG-CSF cDNA and hGH Gene under the Control of Goat Beta-Casein Promoter", 발생과 생식, 14(1), pp.13~19 (2010), 한국발생생물학회
- Palmiter RD, "Helerologous introns can enhance expression of transgenes in mice", Proc Natl Acad Sci USA, 88, pp.478~482 (1991)
- Persuy MA, "High-level, stageand mammary-tissue-specific expression of a caprine kappa-casein-encoding minigene driven by a beta-casein promoter in transgenic mice", Gene, 165, pp.291~296 (1995)
- Reid P, "Pathophysiological roles of osteoprotegerin (OPG)", Eur J Cell Biol, 88, pp.1~17 (2009)
- Ross FP, "Osteoclast biology and bone resorption, In Primer of the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6th ed", pp.30~35 (2006), American Society for Bone and Mineral Research Publication Office
- Rudolph NS, "Biopharmaceutical production in transgenic livestock", Trends Biotechnol, 17, pp.367~374 (1999)
- Simonet WS, "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density", Cell, 89, pp.309~319 (1997)
- Tsuda E, "Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis", Biochem Biophys Res Commun, 234, pp.137~142 (1997)
- Udagawa N, "Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function", Endocrinology, 141, pp.3478~3484 (2000)
- Wan M, "Transcroptional mechanisms of bone morphogenetic protein-induced osteoprotegerin gene expression", J Biol Biochem, 276, pp.10119~10125 (2001)
- Yan JB, "Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity", Biochem Genet, 44, pp.349~360 (2006)
- Yasuda H, "Osteoclast differentiation factor is a ligand for osteoprotegerin", osteoclastogenesis-inhibitory factor and is identical to TRANCE, Proc Natl Acad Sci USA, pp.1998, 95[DOI]